Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter

Coverage

Ascelia Pharma

Ascelia Pharma

Send subscription Close

Ascelia Pharma is a Swedish biopharma company listed on the Nasdaq Stockholm main market since March 2019. The company is focused on the development of a novel non-gadolinium based MRI contrast agent for the detection of liver metastases in cancer patients with impaired kidney function. The product Orviglance has successfully completed clinical Ph 3 (SPARKLE) in 2024 and is now in final preparations towards submission of a NDA to the US FDA in early September. The second pipeline candidate Oncoral (novel oral chemotherapy formulation for gastric cancer) successfully completed Ph 1 and is Ph 2 ready.

Ascelia's lead drug candidate Orviglance has passed clinical development. Remaining risks remain FDA approval (small risk) and failure of meeting commercial targets (greater risk). Ascelia will also need to find a licensing partner to successfully launch the product and prolong the company's financial runway until sufficient revenue is generated from partner milestones and royalties to reach profitability.

Financials

SEKm 2025 2026e 2027e
Sales 0 73,66 71,45
Sales growth (%) N/A N/A -3
EBITDA -74 12 16
EBITDA margin (%) N/A 16,9 22,9
EBIT adj. -74 12 16
EBIT adj. margin (%) N/A 16,9 22,9
Pretax profit -77 12 15
EPS -0,6 0,09 0,12
EPS growth (%) -28,4 N/A 29,6
EPS adj. -0,6 0,09 0,12
Dividend per share 0 0 N/A
EV/EBITDA (x) -4,5 26,2 19,1
EV/EBIT adj. (x) -4,5 26,2 19,1
P/E (x) N/A 32,62 25,18
P/E adj. (x) N/A 32,6 25,2
EV/sales (x) N/A 4,43 4,37
FCF yield (%) -18,7 3,1 4
Le. adj. FCF yld. (%) -18,9 2,9 3,8
Dividend yield (%) 0 0 0
Net IB debt/EBITDA (x) 0,7 -4,8 -4,6
Le. adj. ND/EBITDA (x) 0,7 -4,9 -4,6
SEKm 2025 2026e 2027e
Sales 0 73,66 71,45
COGS 0 0 0
Gross profit 0 74 71
Other operating items -74 -61 -55
EBITDA -74 12 16
Depreciation and amortisation 0 0 0
Depreciation on leased assets 0 0 0
EBITA -74,37 12,45 16,34
Operating EO items 0 0 0
Impairment and amortisation charges 0 0 0
EBIT -74,37 12,45 16,34
Net financial items -2 -1 -1
Pretax profit -77 12 15
Tax 0 0 0
Net profit -76 12 15
Minority interest 0 0 0
Net profit discontinued 0 0 0
Net profit to shareholders -76 12 15
EPS -0,6 0,09 0,12
EPS adj. -0,6 0,09 0,12
Total extraordinary items after tax 0 0 0
Leasing payments 0 0 0
Tax rate (%) 0,6 0 0
Gross margin (%) N/A 100 100
EBITDA margin (%) N/A 16,9 22,9
EBITA margin (%) N/A 16,9 22,9
EBIT margin (%) N/A 16,9 22,9
Pre-tax margin (%) N/A 16,1 21,5
Net margin (%) N/A 16,1 21,5
Sales growth (%) N/A N/A -3
EBITDA growth (%) 9,8 -116,7 31,2
EBITA growth (%) 9,8 -116,7 31,2
EBIT growth (%) 9,8 -116,7 31,2
Net profit growth (%) -4,7 -115,5 29,6
EPS growth (%) -28,4 N/A 29,6
Year N/A N/A N/A
ROE (%) -85,5 11,3 13
ROE adj. (%) -85,5 11,3 13
ROCE (%) -69,6 12,5 14,6
ROCE adj. (%) -69,6 12,5 14,6
ROIC (%) -185,6 24,6 32,3
ROIC adj. (%) -185,6 24,6 32,3
EBITDA adj. -74 12 16
EBITDA adj. margin (%) N/A 16,9 22,9
EBITDA lease adj. -74 12 16
EBITDA lease adj. margin (%) N/A 16,9 22,9
EBITA adj. -74 12 16
EBITA adj. margin (%) N/A 16,9 22,9
EBIT adj. -74 12 16
EBIT adj. margin (%) N/A 16,9 22,9
Pretax profit Adj. -77 12 15
Net profit Adj. -76 12 15
Net profit to shareholders adj. -76 12 15
Net adj. margin (%) N/A 16,1 21,5
SEKm 2025 2026e 2027e
EBITDA -74 12 16
Goodwill 0 0 0
Net financial items -2 -1 -1
Other intangible assets 57 57 57
Paid tax 0 0 0
Tangible fixed assets 0 0 0
Non-cash items 25 0 0
Right-of-use asset 1 1 1
Cash flow before change in WC -52 12 15
Other Fixed Assets All 0 0 0
Change in working capital -21 0 0
Fixed assets 58 58 58
Operating cash flow -72 12 15
Inventories 0 0 0
Capex tangible fixed assets 0 0 0
Receivables 3 3 3
Capex intangible fixed assets 0 0 0
Other current assets 1 1 1
Acquisitions and Disposals 0 0 0
Cash and liquid assets 50 61 75
Free cash flow -72 12 15
Total assets 112 123 137
Shareholders equity 99 110 125
Dividend paid 0 0 0
Minority 0 0 0
Share issues and buybacks 69 0 0
Total equity 99 110 125
Leasing liability amortisation -1 -1 -1
Long-term debt 0 0 0
Other changes in net debt 3 0 0
Pension debt 0 0 0
Convertible debt 0 0 0
Leasing liability 1 1 1
Total other long-term liabilities 0 0 0
Short-term debt 0 0 0
Accounts payable 2 2 2
Other current liabilities 9 9 9
Total liabilities and equity 112 123 137
Net IB debt -49 -60 -74
Net IB debt excl. pension debt -49 -60 -74
Net IB debt excl. leasing -50 -61 -75
Capital employed 100 111 126
Capital invested 51 51 51
Working capital -7 -7 -7
Market cap. diluted (m) 386 386 386
Net IB debt adj. -49 -60 -74
Market value of minority 0 0 0
Reversal of shares and participations 0 0 0
Reversal of conv. debt assumed equity N/A N/A N/A
EV 337 326 312
Total assets turnover (%) 0 62,7 54,9
Working capital/sales (%) N/A -10,1 -10,4
Year N/A N/A N/A
Net debt/equity (%) -49,2 -54,2 -59,5
Net debt / market cap (%) -12,7 -15,5 -19,3
Equity ratio (%) 88,9 89,9 90,9
Net IB debt adj. / equity (%) -49,2 -54,2 -59,5
Current ratio 4,69 5,64 6,91
EBITDA/net interest 31,7 20,3 16,3
Net IB debt/EBITDA (x) 0,7 -4,8 -4,6
Net IB debt/EBITDA lease adj. (x) 0,7 -4,9 -4,6
Interest coverage 12,9 9,7 8,7
SEKm 2025 2026e 2027e
Shares outstanding adj. 128 128 128
Diluted shares adj. 128 128 128
EPS -0,6 0,09 0,12
Dividend per share 0 0 N/A
EPS adj. -0,6 0,09 0,12
BVPS 0,78 0,86 0,98
BVPS adj. 0,33 0,42 0,53
Net IB debt/share -0,38 -0,47 -0,58
Share price 3,02 3,02 3,02
Market cap. (m) 386 386 386
P/E (x) N/A 32,62 25,18
EV/sales (x) N/A 4,43 4,37
EV/EBITDA (x) -4,5 26,2 19,1
EV/EBITA (x) -4,5 26,2 19,1
EV/EBIT (x) -4,5 26,2 19,1
Dividend yield (%) 0 0 0
FCF yield (%) -18,7 3,1 4
Le. adj. FCF yld. (%) -18,9 2,9 3,8
P/BVPS (x) 3,88 3,5 3,09
P/BVPS adj. (x) 9,11 7,23 5,69
P/E adj. (x) N/A 32,6 25,2
EV/EBITDA adj. (x) -4,5 26,2 19,1
EV/EBITA adj. (x) -4,5 26,2 19,1
EV/EBIT adj. (x) -4,5 26,2 19,1
EV/CE (x) 3,4 2,9 2,5
Year N/A N/A N/A
Capex/sales (%) N/A 0 0
Capex/depreciation N/A N/A N/A
Capex tangibles / tangible fixed assets 0 0 0
Capex intangibles / definite intangibles 0 0 0
Depreciation on intang / def. intang 0 0 0
Depreciation on tangibles / tangibles 0 0 0

Equity research

Read earlier research

Media

Ascelia Pharma - Company presentation with CEO Magnus Corfitzen
Ascelia Pharma - Company presentation with CEO Magnus Corfitzen

View more media

Main shareholders -

Main shareholders Share capital % Voting shares % Verified
Nordnet Pensionsförsäkring 10.9 % 10.9 % 25 Feb 2026
Avanza Pension 5.4 % 5.4 % 25 Feb 2026
ÖstVäst Capital Management 3.2 % 3.3 % 9 Oct 2025
Mats Thorén 2.5 % 2.5 % 25 Feb 2026
Handelsbanken Fonder 2.4 % 2.4 % 28 Feb 2026
Philip Bacchus 1.6 % 1.6 % 25 Feb 2026
Swedbank Försäkring 1.2 % 1.2 % 25 Feb 2026
Connys Alltransporter AB 1.1 % 1.1 % 25 Feb 2026
Rafael Gukharyan 1.1 % 1.1 % 25 Feb 2026
Søren Evald Andresen 0.9 % 0.9 % 25 Feb 2026
Source: Holdings by Modular Finance AB